Cardiology
News from the FDA/CDC
Hypertension goes unmedicated in 40% of adults
From the Journals
AHA updates management when CAD and T2DM coincide
From the Journals
Cardiology groups push back on hydroxychloroquine, azithromycin for COVID-19
Both drugs are known to cause torsade de pointes and increase the risk of other arrhythmias, say the AHA, ACC, and HRS.
From the Journals
COVID-19 linked to multiple cardiovascular presentations
Temporary hemodynamic support is shown to help patients with cardiogenic shock, according to case studies.
PURLs
Aspirin, Yes, for at-risk elderly—but what about the healthy elderly?
This study paints a decidedly different picture as to what role—if any—aspirin can play in the primary prevention of CVD for older adults.
Conference Coverage
Enhanced team-based CVD care found to benefit diabetes patients
PHOENIX, ARIZ. – “This implementation strategy could be scaled up within primary care settings in China and other low to middle income countries...
From the Journals
New guidance on management of acute CVD during COVID-19
Expert guidance comes from Chinese cardiology and infectious disease specialists on how to manage severe emergent cardiovascular disease during...
Conference Coverage
New lipid-lowering drug class slashes LDL in HoFH patients
Evinacumab, a broadly active, lipid-lowering drug with a novel mechanism, cut LDL-cholesterol levels by 47% in patients with homozygous familial...
Conference Coverage
Alirocumab effective in homozygous FH
“We’re not getting most patients to goal, but we’re certainly getting them closer to goal.” – Dr. Dirk Blom
News
Dapagliflozin trial in CKD halted because of high efficacy
An independent data monitoring committee recommended stopping the trial.
Conference Coverage
Renal denervation shown safe and effective in pivotal trial
First results of SPYRAL HTN-OFF MED indicate renal denervation may help fill the major unmet need for new treatments for hypertension.